2008 Progress Report on Brain Research [PDF]
Highlights new research on various disorders, nervous system injuries, neuroethics, neuroimmunology, pain, sense and body function, stem cells and neurogenesis, and thought and memory.
Eve Marder +3 more
core
Numerous Fasciola plasminogen-binding proteins may underlie blood-brain barrier leakage and explain neurological disorder complexity and heterogeneity in the acute and chronic phases of human fascioliasis – CORRIGENDUM [PDF]
Javier González‐Miguel +6 more
openalex +1 more source
Corrigendum: Isobaric Tags for Relative and Absolute Quantitation Identification of Blood Proteins Relevant to Paroxetine Response in Patients With Major Depressive Disorder [PDF]
Chin-Chuen Lin +3 more
openalex +1 more source
Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort [PDF]
Jane A. English +14 more
openalex +1 more source
Alterations in blood proteins in the prodromal stage of bipolar II disorders [PDF]
Hyunju Lee +18 more
openalex +1 more source
Genetic Disease Burden, Nutrition and Determinants of Tribal Health Care in Chhattisgarh State of Central-East India: A Status Paper [PDF]
Tribal health is an important aspect of development and progress of the people. This study pertaining to genetic disease burden, nutritional status and biomedical anthropological assessment with particular reference to determinants of tribal health care ...
Balgir, RS
core +1 more source
Fibronectin type-III domain containing protein-5 (FNDC5), predominantly expressed in skeletal muscles, encodes FNDC5 transmembrane-protein. A segment of this protein is cleaved and secreted into blood as irisin, which promotes browning of white adipose ...
Sadaf Majeed +5 more
doaj +1 more source
Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. [PDF]
BackgroundThe purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (
Abbeduto, Leonard +10 more
core

